GENE THERAPY OF PRIMARY &METASTATIC MALIGNANT LIVER TUMORS USING SCH58500

$293,069M01FY2002RRNIH

Emory University, Atlanta GA

Investigators

Linked publications & trials

Paper 39493420 Paper 38633777 Paper 38574700 Paper 38252758 Paper 38195980 Paper 37717845 Paper 37491672 Paper 36651624 Paper 35917919 Paper 35758529 Paper 35307575 Paper 35131442 Paper 35005320 Paper 34907666 Paper 34865854 Paper 34401721 Paper 34352557 Paper 34091237 Paper 33526782 Paper 33478957 Paper 33305291 Paper 33288872 Paper 33230203 Paper 32807060 Paper 32634120 Paper 32446491 Paper 32221144 Paper 32111975 Paper 32056779 Paper 32024598 Paper 31874800 Paper 31857689 Paper 31691959 Paper 31532792 Paper 31427096 Paper 31306866 Paper 31185252 Paper 31171572 Paper 31088850 Paper 30922668 Paper 30855313 Paper 30764648 Paper 30753254 Paper 30737489 Paper 30631138 Paper 30591038 Paper 30124316 Paper 30101556 Paper 29920418 Paper 29872859 Paper 29854969 Paper 29807322 Paper 29564978 Paper 29306690 Paper 29306517 Paper 29290310 Paper 29241359 Paper 29217296 Paper 29203126 Paper 29118087 Paper 29082582 Paper 29040104 Paper 29027660 Paper 28958901 Paper 28944312 Paper 28904075 Paper 28825494 Paper 28660256 Paper 28647272 Paper 28595089 Paper 28532709 Paper 28489609 Paper 28482209 Paper 28460625 Paper 28335624 Paper 28335622 Paper 28283553 Paper 28280039 Paper 28199816 Paper 28158800 Paper 28121636 Paper 28117927 Paper 28027795 Paper 27993381 Paper 27959335 Paper 27955697 Paper 27779124 Paper 27756851 Paper 27622844 Paper 27573938 Paper 27518177 Paper 27493807 Paper 27484667 Paper 27455401 Paper 27423510 Paper 27411977 Paper 27219346 Paper 27176681 Paper 27174641 Paper 27074126

Abstract

This study seeks to determine the safety, biological activity, and effect of SCH 58500 in the local-regional gene therapy of primary and metastatic malignant tumors of the liver which suffer p53 alteration. The study design consists of an open-label, nonrandomized, single-dose, dose-escalation Phase I trial. SCH 58500 will be administered by hepatic artery infusion to patients with primary (hepatocellular cancer) or metastatic (colorectal cancer) tumors of the liver.

View original record on NIH RePORTER →